Periprocedural Anticoagulation Management of Patients With Nonvalvular Atrial Fibrillation

Wysokinski, Waldemar E.; McBane, Robert D.; Daniels, Paul R.; Litin, Scott C.; Hodge, David O.; Dowling, Nicole F.; Heit, John A.
June 2008
Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p639
Academic Journal
OBJECTIVE: To estimate the 3-month cumulative incidence of thromboembolism (TE), bleeding, and death among consecutive patients with nonvalvular atrial fibrillation (AF) who were receiving long-term anticoagulation therapy and were referred to the Thrombophilia Center at Mayo Clinic for periprocedural anticoagulation management. PATIENTS AND METHODS: In a prospective cohort study of consecutive patients receiving long-term anticoagulation therapy who were referred to the Thrombophilia Center for periprocedural anticoagulation management over the 7-year period, January 1, 1997, to December 31, 2003, 345 patients with nonvalvular AF were eligible for inclusion. Warfarin was stopped 4 to 5 days before and was restarted after surgery as soon as hemostasis was assured. The decision to provide bridging therapy with heparin was individualized and based on the estimated risks of TE and bleeding. RESULTS: The 345 patients with AF (mean ± SD age, 74±9 years; 33% women) underwent 386 procedures. Warfarin administration was not interrupted for 44 procedures. Periprocedural heparin was provided for 204 procedures. Patients receiving heparin were more likely to have prior TE (43% vs 24%; P<.001) and a higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (2.2 vs 1.9; P=.06). Four patients had 6 episodes of TE (3 strokes and 3 acute coronary episodes; TE rate, 1.1%; 95% confidence interval, 0.0%-2.1%). Nine patients had 10 major bleeding events (major bleeding rate, 2.7%; 95% confidence interval, 1.0%-4.4%). There were no deaths. Neither bleeding nor TE rates differed by anticoagulant management strategy. CONCLUSION: The 3-month cumulative incidence of TE and bleeding among patients with AF in whom anticoagulation was temporarily interrupted for an invasive procedure was low and was not significantly influenced by bridging therapy.


Related Articles

  • New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation. Hammw�hner, Matthias; D'Alessandro, Alessandra; Wolfram, Oliver; Goette, Andreas // Current Vascular Pharmacology;Jul2007, Vol. 5 Issue 3, p211 

    Atrial fibrillation (AF) is associated with a 6 fold increased risk for ischemic stroke. Observational studies suggest that one in four to five strokes is due to AF. Depending on the risk profile of an individual patient, the yearly risk for ischemic stroke is between 2% and 14%. AF is...

  • Time to try this warfarin alternative? Hickner, John; Rowland, Kate // Clinician Reviews;May2011, Vol. 21 Issue 5, p29 

    The article features the oral anticoagulant dabigatran that is used to prevent stroke and thromboembolism in patients with atrial fibrillation. It is considered as an alternative for warfarin which requires repeated monitoring due to possible occurrences of both major and minor bleeding. Results...

  • Left Atrial Appendage Closure: Initial Experience with the Watchman Device. Toutouzas, Konstantinos; Trantalis, George; Benetos, Georgios; Sideris, Skevos; Aggeli, Konstantina; Stefanadis, Christodoulos // Hospital Chronicles;2014, Vol. 9 Issue 2, p1 

    We herein present the first left atrial appendage (LAA) percutaneous closure procedure performed in our Institution with use of the Watchman device in an 82-year old woman with atrial fibrillation, unable to continue receiving anticoagulation therapy due to bleeding complications. A propos with...

  • Atrial fibrillation guidelines for management: what's new? Berry, Ellen; Padgett, Helen; Holton, Cathy // British Journal of Cardiac Nursing;Sep2015, Vol. 10 Issue 9, p426 

    Atrial fibrillation (AF) is the most common cardiac arrhythmia and can present as either an acute or chronic condition. AF is a global health-care problem with evidence suggesting an increasing prevalence and incidence worldwide (Chugh et al, 2014). It affects 1-2% of the general population...

  • Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry. Eapen, Zubin J.; Xiaojuan Mi; Fonarow, Gregg C.; Setoguchi, Soko; Piccini, Jonathan P.; Mills, Roger M.; Klaskala, Winslow; Curtis, Lesley H.; Hernandez, Adrian F. // JAFIB: Journal of Atrial Fibrillation;Dec2013/Jan2014, Vol. 6 Issue 4, p10 

    The risks and benefits of anticoagulation for patients with both heart failure and atrial fibrillation are unclear. We hypothesized that anticoagulation was associated with improved clinical outcomes of heart failure patients with atrial fibrillation independent of other risk factors. We...

  • Acute Management of Atrial Fibrillation: Part II. Prevention of Thromboembolic Complications. King, Dana E.; Dickerson, Lori M.; Sack, Jonathan L. // American Family Physician;7/15/2002, Vol. 66 Issue 2, p261 

    Part II. Focuses on the prevention of thromboembolic complications using anticoagulation. Background on atrial fibrillation; Information on several anticoagulant drugs; Consideration of long-term anticoagulation therapy.

  • Anticoagulation in Patients with Heart Failure. Bhatia, R. Sacha; Ouzounian, Maral; Tu, Jack V.; Liu, Peter P.; Lee, Douglas S. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2009, Vol. 7 Issue 3, p193 

    The decision to anti-coagulate patients with heart failure (HF) is a difficult one, with limited data available to support clinical judgment. Thromboembolic complications, both arterial (stroke) and venous (deep vein thrombosis and pulmonary embolism), remain a significant cause of mortality and...

  • Thromboembolism in heart failure: who should be treated? Diet, Frank; Erdmann, Erland // European Journal of Heart Failure;Dec2000, Vol. 2 Issue 4, p355 

    The risk of thromboembolic complications in patients with heart failure and/or chronic left-ventricular systolic dysfunction is increased. Nevertheless, anticoagulant therapy in these patients is still a subject of debate. Atrial fibrillation is the only prospectively evaluated, proven...

  • Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Sadanaga, Tsuneaki; Kohsaka, Shun; Mitamura, Hideo; Ogawa, Satoshi // Heart & Vessels;Sep2011, Vol. 26 Issue 5, p530 

    The aim of the present study was to assess whether elevated B-type natriuretic peptide (BNP) levels, as an objective marker of heart failure, is a predictor of subsequent thromboembolic events in patients with atrial fibrillation (AF) during oral anticoagulant therapy. This was a post hoc...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics